GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Moberg Pharma AB (OTCPK:MBGPF) » Definitions » EBITDA Margin %

MBGPF (Moberg Pharma AB) EBITDA Margin % : -545.16% (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Moberg Pharma AB EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Moberg Pharma AB's EBITDA for the three months ended in Dec. 2024 was $-0.51 Mil. Moberg Pharma AB's Revenue for the three months ended in Dec. 2024 was $0.09 Mil. Therefore, Moberg Pharma AB's EBITDA margin for the quarter that ended in Dec. 2024 was -545.16%.


Moberg Pharma AB EBITDA Margin % Historical Data

The historical data trend for Moberg Pharma AB's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moberg Pharma AB EBITDA Margin % Chart

Moberg Pharma AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -8,120.00 - -192.95

Moberg Pharma AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -865.82 -121.17 -32.36 -545.16

Competitive Comparison of Moberg Pharma AB's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Moberg Pharma AB's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Moberg Pharma AB's EBITDA Margin % falls into.


;
;

Moberg Pharma AB EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Moberg Pharma AB's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-1.723/0.893
=-192.95 %

Moberg Pharma AB's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-0.507/0.093
=-545.16 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Moberg Pharma AB  (OTCPK:MBGPF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Moberg Pharma AB EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Moberg Pharma AB's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Moberg Pharma AB Business Description

Traded in Other Exchanges
Address
Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51
Moberg Pharma AB is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of compounds. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.